716 related articles for article (PubMed ID: 12600227)
21. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis.
Beresford R; Ward A
Drugs; 1987 Jan; 33(1):31-49. PubMed ID: 3545764
[TBL] [Abstract][Full Text] [Related]
22. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
Gunasekara NS; Spencer CM; Keating GM
Drugs; 2002; 62(8):1217-51. PubMed ID: 12010089
[TBL] [Abstract][Full Text] [Related]
23. Depot pipothiazine palmitate and undeclynate for schizophrenia.
Quraishi S; David A
Cochrane Database Syst Rev; 2000; (2):CD001720. PubMed ID: 10796448
[TBL] [Abstract][Full Text] [Related]
24. Long-acting injectable antipsychotics in the elderly: guidelines for effective use.
Masand PS; Gupta S
Drugs Aging; 2003; 20(15):1099-110. PubMed ID: 14651433
[TBL] [Abstract][Full Text] [Related]
25. Depot fluphenazine for schizophrenia.
Adams CE; Eisenbruch M
Cochrane Database Syst Rev; 2000; (2):CD000307. PubMed ID: 10796340
[TBL] [Abstract][Full Text] [Related]
26. Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy.
Stanković Z; Ille T
Vojnosanit Pregl; 2013 Mar; 70(3):267-73. PubMed ID: 23607237
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.
Ereshefsky L; Mascarenas CA
J Clin Psychiatry; 2003; 64 Suppl 16():18-23. PubMed ID: 14680415
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.
Correll CU; Kim E; Sliwa JK; Hamm W; Gopal S; Mathews M; Venkatasubramanian R; Saklad SR
CNS Drugs; 2021 Jan; 35(1):39-59. PubMed ID: 33507525
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations.
Knudsen P
Acta Psychiatr Scand Suppl; 1985; 322():51-75. PubMed ID: 2866666
[TBL] [Abstract][Full Text] [Related]
30. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.
Gentile S
Pharmacotherapy; 2013 Oct; 33(10):1087-106. PubMed ID: 23776129
[TBL] [Abstract][Full Text] [Related]
31. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
32. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
Bishara D; Taylor D
Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393
[TBL] [Abstract][Full Text] [Related]
33. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
34. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
Bhanji NH; Chouinard G; Margolese HC
Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
[TBL] [Abstract][Full Text] [Related]
35. [Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].
Carpiniello B; Mellino G; Pintore S; Puddu L; Pinna F
Clin Ter; 2011; 162(4):331-41. PubMed ID: 21912821
[TBL] [Abstract][Full Text] [Related]
36. Olanzapine pamoate for the treatment of schizophrenia.
Naber D
Expert Opin Pharmacother; 2011 Mar; 12(4):627-33. PubMed ID: 21254860
[TBL] [Abstract][Full Text] [Related]
37. Long-term depot antipsychotics. A risk-benefit assessment.
Barnes TR; Curson DA
Drug Saf; 1994 Jun; 10(6):464-79. PubMed ID: 7917075
[TBL] [Abstract][Full Text] [Related]
38. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics.
Chue P; Emsley R
CNS Drugs; 2007; 21(6):441-8. PubMed ID: 17521224
[TBL] [Abstract][Full Text] [Related]
39. Clinical review of a long-acting, injectable formulation of risperidone.
Knox ED; Stimmel GL
Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
[TBL] [Abstract][Full Text] [Related]
40. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed.
Meyer JM
CNS Spectr; 2017 Dec; 22(S1):14-28. PubMed ID: 29350127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
